Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

NCT03406715 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

14

Enrollment

OTHER

Sponsor class

Stopped Sponsor closed study

Conditions

Small Cell Lung Cancer
Lung Cancer
Relapsed Small Cell Lung Cancer

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
BIOLOGICAL: Dendritic Cell based p53 Vaccine

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]